"We are excited about our upcoming milestones, including the opportunity to share new clinical data from the FIREFLY-1 trial in an oral presentation at ASCO," said Jeremy Bender, Ph.D., chief executive officer of Day One. "We are also thrilled to announce the appointment of two industry veterans to Day One’s executive leadership team. Lauren Merendino will join as Chief Commercial Officer and Dr. Raphael Rousseau will join as Chief Medical Officer. Paired with the promotion of our co-founder Dr. Samuel Blackman to Head of Research and Development, these key appointments will help shape our future and contribute to long-term value creation for the company."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on DAWN:
- Day One Reports First Quarter 2023 Financial Results and Corporate Progress
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Day One Announces Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Day One Biopharmaceuticals double downgraded at BofA on regulatory risks
